Actuate Therapeutics (NASDAQ:ACTU) Now Covered by Craig Hallum

Craig Hallum initiated coverage on shares of Actuate Therapeutics (NASDAQ:ACTU) in a research note issued to investors on Tuesday, MarketBeat.com reports. The brokerage issued a buy rating and a $21.00 price objective on the stock.

Separately, HC Wainwright assumed coverage on Actuate Therapeutics in a research report on Monday, March 17th. They set a “buy” rating and a $20.00 target price on the stock.

Actuate Therapeutics Stock Performance

NASDAQ ACTU opened at $8.52 on Tuesday. The company’s fifty day moving average is $7.39 and its two-hundred day moving average is $8.05. Actuate Therapeutics has a 52-week low of $5.51 and a 52-week high of $11.73.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. OMERS ADMINISTRATION Corp bought a new stake in Actuate Therapeutics in the 4th quarter valued at $84,000. Mercer Global Advisors Inc. ADV bought a new stake in Actuate Therapeutics in the fourth quarter valued at about $130,000. Voss Capital LP bought a new position in Actuate Therapeutics during the fourth quarter worth about $440,000. Envestnet Asset Management Inc. acquired a new stake in Actuate Therapeutics in the 4th quarter valued at $83,000. Finally, BIOS Capital Management LP acquired a new stake in shares of Actuate Therapeutics in the 4th quarter valued at $78,753,000.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.